Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial

Quality of Life Research

Volumn 18, Issue 2, 2009, Pages 147-155

  Moinpour, Carol M ^a   Donaldson, Gary W ^b   Nakamura, Yoshio ^b  

^a SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Causal effect; Individual differences; Mediation; Moderated intervention; Relational outcome

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; HUMAN; MALE; MCGILL PAIN QUESTIONNAIRE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PERFORMANCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; HUMANS; MALE; MITOXANTRONE; MODELS, STATISTICAL; NEOPLASMS, HORMONE-DEPENDENT; PAIN; PAIN MEASUREMENT; PREDNISONE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME;

EID: 59849124032     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-008-9433-3     Document Type: Article

References (26)

1. GW Donaldson 2003 General linear contrasts on latent variable means: Structural equation hypothesis tests for multivariate clinical trials Statistics in Medicine 22 2893 2917 10.1002/sim.1558
2. GW Donaldson CM Moinpour 2002 Individual differences in quality-of-life treatment response Medical Care 40 6 Suppl III39 III53 10.1097/00005650- 200206001-00007
3. CM Moinpour GW Donaldson MW Redman 2007 Do general dimensions of quality of life add clinical value to symptom data? Journal of the National Cancer Institute. Monographs 37 31 38 10.1093/jncimonographs/lgm007
4. DP Petrylak CM Tangen MHA Hussein PN Lara Jr JA Jones ME Taplin 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer The New England Journal of Medicine 351 15 1513 1520 10.1056/NEJMoa041318
5. DL Berry CM Moinpour CS Jiang DP Ankerst DP Petrylak LV Vinson 2006 Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone Journal of Clinical Oncology 24 18 2828 2835 10.1200/JCO.2005.04.8207
6. NM Laird JH Ware 1982 Random-effects models for longitudinal data Biometrics 38 963 974
7. PJ Curran AM Hussong 2003 The use of latent trajectory models in psychopathology research Journal of Abnormal Psychology 112 4 526 544 10.1037/0021-843X.112.4.526
8. Singer, J. D., & Willett, J. B. (2003). Applied longitudinal data analysis: Modeling changes and event occurrence. New York: Oxford University Press.
9. Kline, R. B. (2005). Principles and practice of structural equation modeling. New York: Guilford Press.
10. VJ Sinibaldi MA Carducci S Moore-Cooper M Laufer M Zahurak MA Eisenberger 2002 Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma Cancer 94 5 1457 1465 10.1002/cncr.10350
11. IF Tannock D Osoba MR Stockler DS Ernst AJ Neville MJ Moore 1996 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points Journal of Clinical Oncology 14 6 1756 1764
12. R Melzack 1987 The short-form McGill pain questionnaire Pain 30 191 197 10.1016/0304-3959(87)91074-8
13. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez European Organization for Research, Treatment of Cancer Study Group on Quality of Life 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology Journal of the National Cancer Institute 85 5 365 376 10.1093/jnci/85.5.365
14. Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., et al. (2001). EORTC QLQ-C30 scoring manual. Brussels: EORTC.
15. G Borghede M Sullivan 1996 Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30 Quality of Life Research 5 212 222 10.1007/BF00434743
16. Muthén, L. K., & Muthén, B. (1998-2005). Mplus user's guide. Los Angeles: Muthén & Muthén.
17. Pearl, J. (2000). Causality: Models, reasoning, and inference. Cambridge: Cambridge University Press.
18. RM Baron DA Kenny 1986 The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations Journal of Personality and Social Psychology 51 1173 1182 10.1037/0022-3514.51.6.1173
19. CM Judd DA Kenny 1981 Process analysis: Estimating mediation in treatment evaluations Evaluation Review 9 602 618 10.1177/0193841X8100500502
20. DP MacKinnon AJ Fairchild MS Fritz 2007 Mediation analysis Annual Review of Psychology 58 593 614 10.1146/annurev.psych.58.110405.085542
21. JM Albert 2008 Mediation analysis via potential outcomes models Statistics in Medicine 27 8 1282 1304 10.1002/sim.3016
22. HC Kraemer GT Wilson CG Fairburn WS Agras 2002 Mediators and moderators of treatment effects in randomized clinical trials Archives of General Psychiatry 59 10 877 883 10.1001/archpsyc.59.10.877
23. Kraemer, H. C., Lowe, K. K., & Kupfer, D. J. (2005). To your health: How to understand what research tells us about risk. New York: Oxford University Press.
24. HC Kraemer E Stice A Kazdin D Offord D Kupfer 2001 How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors The American Journal of Psychiatry 158 6 848 856 10.1176/appi.ajp.158.6.848
25. Edwards, D. (1995). Introduction to graphical modeling. New York: Springer-Verlag.
26. Edwards, D. (1995). MIM release 3.2. Boston: Free Software Foundation.